Wire · opportunities
Q&A: Steve Yoelin, MD, on the Evolving Regulatory Landscape for Masseter Toxin
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 September 2026 · Fusion42 review
The FDA is reviewing a supplemental Biologics License Application for onabotulinumtoxinA (BOTOX Cosmetic) to treat masseter muscle prominence on-label. This regulatory move would standardize treatment protocols, improve injector confidence, and enhance patient counseling in aesthetic dermatology.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
Injectors in aesthetic dermatology can now expect clearer treatment standards and lower legal uncertainty as the FDA moves toward approving BOTOX for masseter muscle shaping. You need to update your practice protocols and patient discussions to align with these forthcoming official guidelines.
◆ Coverage
1 source · 10 Sep 2026
◆ Related on Wire
◆ Topics